QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 why-is-scholar-rock-stock-trading-lower-on-monday

Scholar Rock stock falls as FDA issues Form 483 to Catalent; company to meet FDA, while apitegromab shows lean mass preservatio...

Core News & Articles

https://scholarrock.com/our-company/newsroom/update-on-third-party-manufacturing-site/

 b-of-a-securities-initiates-coverage-on-scholar-rock-holding-with-buy-rating-announces-price-target-of-53

B of A Securities analyst Tazeen Ahmad initiates coverage on Scholar Rock Holding (NASDAQ:SRRK) with a Buy rating and announ...

 crinetics-pharmaceuticals-blackberry-perpetua-resources-and-other-big-stocks-moving-higher-on-friday

U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Friday. Shares of Crinetics Pharmaceutical...

 piper-sandler-maintains-overweight-on-scholar-rock-holding-lowers-price-target-to-51

Piper Sandler analyst Allison Bratzel maintains Scholar Rock Holding (NASDAQ:SRRK) with a Overweight and lowers the price ta...

 barclays-maintains-overweight-on-scholar-rock-holding-lowers-price-target-to-44

Barclays analyst Etzer Darout maintains Scholar Rock Holding (NASDAQ:SRRK) with a Overweight and lowers the price target fro...

 scholar-rocks-spinal-muscular-atrophy-drug-faces-fda-delay-over-catalent-indiana-inspection

FDA cites Catalent Indiana issues in Scholar Rock's SMA drug review; European approval decision expected in 2026, with Germ...

 barclays-initiates-coverage-on-scholar-rock-holding-with-overweight-rating-announces-price-target-of-45

Barclays analyst Etzer Darout initiates coverage on Scholar Rock Holding (NASDAQ:SRRK) with a Overweight rating and announce...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION